+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116)



Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116)



Journal of Pharmacology and Experimental Therapeutics 266(1): 114-120



The angiotensin II (AII) antagonistic action of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-1H-benzi mid azole-7 - carboxylic acid (CV-11974) was examined in in vitro assay systems, including AII receptor binding assay using membrane fractions of bovine adrenal cortex or rabbit aorta and AII-induced contraction assay using rabbit aortic strips, and CV-11974 and its prodrug, (+/-)1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), were examined in an in vivo system of AII-induced pressor response in conscious rats. DuP 753 or EXP3174 (the main active metabolite of DuP 753) was used as the reference compound. CV-11974 inhibited the binding of [125I] AII to the bovine adrenal cortical membrane and rabbit aortic membrane with IC50 values of 1.12 x 10(-7) and 2.86 x 10(-8) M, respectively. Similar results were obtained with EXP3174. CV-11974 interacted with AII in these membrane fractions with subtype 1 receptor in a competitive manner. CV-11974 at 10(-5) M did not affect the binding of [125I]AII to subtype 2 (AT2) receptor in bovine cerebellum. CV-11974 selectively inhibited the AII-induced contraction of rabbit aortic strips in a noncompetitive manner (pD' 2, 9.97); it had no effects on the contraction induced by norepinephrine, KCl, serotonin, prostaglandin F2 alpha or endothelin. EXP3174 showed a pD'2 value of 8.95 for the AII-induced contraction. CV-11974 given intravenously and TCV-116 given orally inhibited the AII-induced pressor response in rats with ID50 values of 0.033 mg/kg and 0.069 mg/kg, respectively. These effects of CV-11974 and TCV-116 were 12 and 48 times more potent than those of EXP3174 and DuP 753, respectively.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046968695

Download citation: RISBibTeXText

PMID: 8331552


Related references

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 268(3): 1540-1547, 1994

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions. Arzneimittel-Forschung 46(7): 681-686, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (racemic)-1-(Cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl)-1H-benzimidazole-7-carboxylate: Part II: Effect on cardiovascular system and renal functions. Arzneimittel Forschung 46(7): 681-686, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties. Arzneimittel-Forschung 46(6): 572-579, 1996

General pharmacological properties of the new angiotensin II receptor antagonist (racemic)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-benzimidazole-7-carboxylate. Part I. Effects on central nervous system and other properties. Arzneimittel Forschung 46(6): 572-579, 1996

The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats. Journal of Pharmacology and Experimental Therapeutics 277(2): 572-577, 1996

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1 biphenyl-4-yl-1H-benzimidazole-7-carboyxlic acid. Journal of Pharmacology & Experimental Therapeutics 266(1): 114-120, 1993

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, -1- ethyl 2-ethoxy-1- bipenyl-4-yl-methyl-1H-benzimidazole-7-carboxylate. Journal of Pharmacology & Experimental Therapeutics 268(3): 1540-1547, 1994

The angiotensin receptor antagonist 2-ethoxy-1- biphenyl-4-ylmethyl-1H-benzimidazole-7-carboxylic acid. Journal of Pharmacology & Experimental Therapeutics 277(2): 572-577, 1996

Evaluation and improvement of bioavailability of a new angiotensin II receptor antagonist, 2-butyl-1- biphenyl-4-yl methyl-1H-benzimidazole-7-carboxylic acid by making prodrug. International Journal of Pharmaceutics (Amsterdam) 103(1): 1-7, 1994

Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist. Bioorganic and Medicinal Chemistry Letters 21(3): 1036-1040, 2011

Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-((5-ethyl-3-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl-1,3,4-thiadiazoline-2-ylidene)aminocarbonyl)-1-cyclopentencarboxylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittel Forschung 47(10): 1099-1103, 1997

Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventricular failure. Arzneimittel-Forschung 47(10): 1099-1103, 1997

A non-peptide angiotensin II receptor antagonist: 2-butyl-6-dimethoxymethyl-5-phenyl-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-imidazo[5,4-b]pyridine. Acta Crystallographica. Section C Crystal Structure Communications 52: 1019-1022, 1996

Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996). Journal of Medicinal Chemistry 36(16): 2253-2265, 1993